ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 60

Epidemiology of Polymyalgia Rheumatica in Korea

In young Kim1, Seulkee Lee1, Hemin Jeong1, Hyungjin Kim1, Jiwon Hwang1, Jaejoon Lee2, Eun-mi Koh1 and Hoon-Suk Cha1, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: polymyalgia rheumatica

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More

Session Type: Abstract Submissions (ACR)

Background/Purpose

Polymyalgia rheumatica (PMR) is a chronic inflammatory disease affecting people older than 50 years. Diagnosis is made based on clinical features and the current standard of treatment is low-dose glucocorticoids. PMR is known to be more frequent in Caucasian ethnicity and females. But up to date, there has been a scant epidemiologic study of PMR in Asian countries including Korea. We aimed to estimate incidence and prevalence rates of PMR and current treatment state in Korea.

Methods

We performed nationwide retrospective review of PMR using the Korean National Health Insurance (NHI) and Health Insurance Review and Assessment (HIRA) database from 2007 to 2012.  NHI is the sole public medical insurance system in Korea, which covers 100% of the Korean population and HIRA is a government incorporated organization to build an accurate claims review and quality assessment system for the NHI. We defined PMR cases by both diagnostic codes and medication codes simultaneously, in other words, by proper ICD code (M 35.3) and concurrent appropriate prescription codes (glucocorticoids).

Results

We identified total 1,463 newly diagnosed cases of PMR for the 5 years. The annual incidence rate of PMR per 100,000 Korean individuals was estimated as 2.06 (1.45 in male, 2.59 in female), and the prevalence rate was 8.21 per 100,000 individuals in 2012 (5.60 in male, 10.42 in female). Among the 1,463 cases, 992 (67.8%) were female and 471 (32.2%) were male and the median age at the time of diagnosis was 67 years old. The incidence rate according to age appeared to increase with advancing age peaking 70 years old, as similar as previous reports of western studies. The most frequently prescribed agent was prednisolone, and the starting daily dosage of glucocorticoids as prednisolone equivalent was between 5 to 15 mg daily in 74.5 % of the patients.

Conclusion

This is the first study that evaluated epidemiologic data of PMR in Korea, and included population was the largest among those of studies published in East Asia so far. The incidence and prevalence rates of PMR are estimated considerably lower than that of Western populations. And this result supports that both genetic and environmental factor would play important roles in pathogenesis of PMR.


Disclosure:

I. Y. Kim,
None;

S. Lee,
None;

H. Jeong,
None;

H. Kim,
None;

J. Hwang,
None;

J. Lee,
None;

E. M. Koh,
None;

H. S. Cha,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-of-polymyalgia-rheumatica-in-korea/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology